^
    2ms
    Immunohistochemistry expression of membrane targets for novel therapeutic agents in RET-rearranged NSCLC (AACR 2024)
    cMET and TROP2 were frequently expressed in RET+ aNSCLC, EGFR and HER3 were present in a lower proportion, HER2 was rarely found. These markers were not associated with a prognostic or predictive impact on RETi outcomes. The activity of novel therapeutic agents should be evaluated in this setting.
    PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression • HER-2 expression • MET amplification • RET fusion • EGFR expression • ERBB3 expression • MET expression • RET expression
    |
    Dako EGFR pharmDx™ • PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
    1year
    Expression of molecular targets for antibody-drug conjugates in patients with NSCLC and RET fusions (AACR 2023)
    PD-L1 expression did not show significant difference between pts with positive vs negative EGFR or HER3 staining (p=1).Conclusions EGFR and HER3 had variable expression in RET+ NSCLC, deserving further exploration for novel treatment strategies. HER2 expression was not found in our RET cohort.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • RET (Ret Proto-Oncogene) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • KIF5B (Kinesin Family Member 5B) • ANKRD26 (Ankyrin Repeat Domain Containing 26)
    |
    PD-L1 expression • HER-2 expression • RET fusion • EGFR expression • ERBB3 expression • KIF5B-RET fusion • EGFR negative • ERBB4 expression • RET expression
    |
    Dako EGFR pharmDx™ • PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
    over3years
    EGFR, BRCA1, BRCA2 and TP53 genetic profile in Moroccan triple negative breast cancer cases. (PubMed, Int J Mol Epidemiol Genet)
    Regarding BRCA2 and EGFR sequencing results, no mutations or other genetic alterations were detected in 39 patients that were successfully sequenced. Statistical analysis revealed the absence of any correlations.
    Journal • Clinical • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    TP53 mutation • BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 expression • EGFR expression • EGFR overexpression
    |
    Dako EGFR pharmDx™